Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naive Patients with Early Active Rheumatoid Arthritis (Duration ≤2 Years): Results of an Exploratory Phase 2 MRI Study.

被引：0

作者：

Conaghan, Philip G. ^{[1
,2
]}

Ostergaard, M. ^{[3
]}

Wu, C. ^{[4
]}

van der Heijde, D. ^{[5
]}

Irazoque-Palazuelos, F. ^{[6
]}

Hrycaj, P. ^{[7
]}

Xie, Z. ^{[8
]}

Zhang, R. ^{[8
]}

Wyman, B. T. ^{[8
]}

Bradley, J. D. ^{[8
]}

Soma, K. ^{[8
]}

Wilkinson, B. ^{[8
]}

机构：

[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

[2] Chapel Allerton Hosp, NIHR Leeds Musculoskeletal Biomed Res Unit, Leeds, W Yorkshire, England

[3] Copenhagen Ctr Arthrit Res, Glostrup, Denmark

[4] BioClinca Inc, Newark, CA USA

[5] Leiden Univ, Med Ctr, Leiden, Netherlands

[6] Hosp Angeles Mocel, Serv Reumatol, Mexico City, DF, Mexico

[7] Poznan Univ Med Sci, Poznan, Poland

[8] Pfizer Inc, Groton, CT 06340 USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2014年 / 66卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1181

引用

页码：S519 / S520

页数：2

共 38 条

[21] RESULTS FROM A MULTICENTER, INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Hsu, B.
Sheng, S.
Weinblatt, M. E.
Smolen, J. S.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 61 - 61
[22] FILGOTINIB (GLPG0634), AN ORAL JAK1 SELECTIVE INHIBITOR IS EFFECTIVE IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS: RESULTS FROM A 24-WEEK PHASE 2B DOSE RANGING STUDY
Westhovens, R.
Alten, R.
Pavlova, D.
Sosa, F. E. Enriquez
Mazur, M.
Greenwald, M.
Van der Aa, A.
Vanhoutte, F.
Tasset, C.
Harrison, P.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 142 - 142
[23] Toreforant, an orally active histamine H4-receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study
Boyle, David L.
DePrimo, Samuel E.
Calderon, Cesar
Chen, Dion
Dunford, Paul J.
Barchuk, William
Firestein, Gary S.
Thurmond, Robin L.
INFLAMMATION RESEARCH, 2019, 68 (04) : 261 - 274
[24] Results From a Multicenter, International, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-IL-6 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy.
Hsu, Benjamin
Sheng, Shihong
Weinblatt, Michael E.
Smolen, Josef
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1035 - S1035
[25] Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Panchakshari, Rohit
Loza, Matthew
Huizinga, Thomas
Schett, Georg
Ma, Keying
Leu, Jocelyn H.
Liva, Sophia G.
Ibrahim, Fowzia
Zhou, Bei
Wang, Qingmin
Cella, Ricardo Rojo
Karyekar, Chetan S.
Fei, Kaiyin
Cuff, Carolyn
Gao, Sheng
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4231 - 4232
[26] RESULTS FROM A 2-PART, PROOF-OF-CONCEPT, DOSE-RANGING, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF SIRUKUMAB, A HUMAN ANTI-IL-6 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
Hsu, B.
Sheng, S.
Smolen, J. S.
Weinblatt, M. E.
ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 188 - 188
[27] Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naive patients with active psoriatic arthritis
Gottlieb, Alice B.
McInnes, Iain B.
Rahman, Proton
Kollmeier, Alexa P.
Xu, Xie L.
Jiang, Yusang
Sheng, Shihong
Shawi, May
Chakravarty, Soumya D.
Lavie, Frederic
Mease, Philip J.
RMD OPEN, 2023, 9 (01):
[28] Results From a 2-Part, Proof-of-Concept, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Sirukumab, a Human Anti-Interleukin-6 Monoclonal Antibody, in Active Rheumatoid Arthritis Patients Despite Methotrexate Therapy.
Hsu, Benjamin
Sheng, Shihong
Smolen, Josef
Weinblatt, Michael
ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1034 - S1034
[29] Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis: results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)
Moller-Bisgaard, S.
Ejbjerg, B. J.
Eshed, I.
Horslev-Petersen, K.
Hetland, M. L.
Jurik, A. G.
Thomsen, H.
Torfing, T.
Stengaard-Pedersen, K.
Junker, P.
Krogh, N. S.
Lottenburger, T.
Ellingsen, T.
Andersen, L. S.
Skjodt, H.
Svendsen, A. J.
Tarp, U.
Hansen, I. T.
Podenphant, J.
Pedersen, J. K.
Lindegaard, H.
Hanson, L. G.
Vestergaard, A.
Glinatsi, D.
Ostergaard, M.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2017, 46 (05) : 335 - 345
[30] Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Atsumi, Tatsuya
Tanaka, Yoshiya
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Yamanaka, Hisashi
Ishiguro, Naoki
Eguchi, Katsumi
Watanabe, Akira
Origasa, Hideki
Yasuda, Shinsuke
Yamanishi, Yuji
Kita, Yasuhiko
Matsubara, Tsukasa
Iwamoto, Masahiro
Shoji, Toshiharu
Togo, Osamu
Okada, Toshiyuki
van der Heijde, Desiree
Miyasaka, Nobuyuki
Koike, Takao
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1348 - 1356

← 1 2 3 4 →